Introduction Transcatheter aortic valve implantation (TAVI) as a treatment in severe aortic stenosis (AS) is an excellent alternative to conventional surgical replacement. However, long-term outcomes are not benign. Reninangiotensin system (RAS) blockade has shown benefit in terms of adverse remodelling in severe AS and after surgical replacement. Methods and analysis The RAS blockade after TAVI (RASTAVI) trial aims to detect if there is a benefit in clinical outcomes and ventricular remodelling with this therapeutic strategy following the TAVI procedure. The study has been designed as a randomised 1:1 open-label study that will be undertaken in 8 centres including 336 TAVI recipients. All patients will receive the standard treatment. The active treatment group will receive ramipril as well. Randomisation will be done before discharge, after signing informed consent. All patients will be followed up for 3 years. A cardiac magnetic resonance will be performed initially and at 1 year to assess ventricular remodelling, defined as ventricular dimensions, ejection fraction, ventricular mass and fibrosis. Recorded events will include cardiac death, admission due to heart failure and stroke. The RASTAVI Study will improve the management of patients after TAVI and may help to increase their quality of life, reduce readmissions and improve longterm survival in this scenario. Ethics and dissemination All authors and local ethics committees have approved the study design. All patients will provide informed consent. Results will be published irrespective of whether the findings are positive or negative. Trial registration number NCT03201185.
InTRoduCTIon
Aortic stenosis (AS) is the result of a slow progressive disease related to atherosclerosis, inflammation, haemodynamic factors and active calcification. 1 It presents an age-related growing incidence as a result of these degenerative mechanisms and, therefore, it has a great impact in the ageing population of developed countries. 2 In parallel, old patients often present an increased risk for conventional surgery due to frailty and comorbidities. For this reason, in the last decade the use of transcatheter aortic valve implantation (TAVI) as a less invasive alternative to treat AS has increased exponentially.
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Strengths and limitations of this study ► Ventricular remodelling following tanscatheter aortic valve implantation (TAVI) has not been studied much, to date. This is the first study to prospectively explore the impact of renin-angiotensin system (RAS) modulation in this scenario; in addition, the consequences of RAS blockade in major outcomes of patients harbouring a TAVI device will also be explored. ► The design as a randomised 1:1 open label study (ramipril vs standard care) and the vast experience of the participating institutions will confer great validity to future findings. ► Also, the central analysis of cardiac magnetic resonance examinations will increase the accuracy of measurements and, therefore, validity. ► As a limitation, bias could be derived from the unblinded nature of the study for the treating specialist; external monitoring will be performed to control this risk.
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Several studies have demonstrated the benefits of TAVI in high-risk and intermediate-risk patients, [3] [4] [5] [6] [7] but clinical practice has rapidly moved forward in this scenario, often beyond current evidence and despite a number of unanswered questions remaining, that include the identification of factors with potential impact in long-term outcomes. 8 In particular, the presence of fibrosis and myocardial hypertrophy in patients with AS has been related to worse prognosis especially if they persist once the valvular obstruction has been treated. [9] [10] [11] [12] [13] Therefore, better outcomes may be achieved with the use of strategies improving cardiac remodelling by reversing fibrosis and hypertrophy. [14] [15] [16] In this regard, renin-angiotensin system (RAS) blockade has been shown to have a positive impact in remodelling and in major clinical outcomes in alternative scenarios. [17] [18] [19] [20] [21] [22] [23] [24] In particular, its use in patients with AS and in those undergoing conventional surgery, has demonstrated consistent benefit. [25] [26] [27] [28] However, there are no data regarding the effects of this therapy for TAVI recipients.
The RAS blockade after TAVI (RASTAVI) Study (http://www. ClinicalTrials. gov NCT03201185) aims to investigate the effect of adding ramipril to the standard care in patients successfully treated with TAVI in terms of ventricular remodelling as assessed by cardiac magnetic resonance (CMR) and in the main clinical outcomes.
METhodS And AnAlySIS
The RASTAVI Study is a national, multicentre, open-label and randomised 1:1 trial aiming to determine the effect of ramipril on cardiac events, functional capacity and the evolution of cardiac remodelling on patients with AS undergoing TAVI. Online supplementary files 1-3 show the official version of the protocol, the financial sources and the model consent form, respectively.
Patients across eight centres (summarised in table 1) will be randomised to receive conventional treatment or conventional treatment plus ramipril. Regular pathways exist to communicate important protocol modifications if any. Workflow has been schematically depicted in figure 1. Briefly, after initial clinical evaluation to determine the suitability of the candidate, informed consent will be obtained by the investigators and standard baseline evaluation including transthoracic echocardiography, blood tests and 6-minutes walk test will be performed. After the TAVI procedure the patients will be randomised to receive either standard care or an initial dose of ramipril (2.5 mg). Titration of the ramipril dose will be performed at 1-month and 3 month follow-up visits aiming 10 mg daily if tolerated; in case there are symptoms related to dose increase, it will be reduced to the previous dose. Patients in the control group will not receive RAS inhibitors throughout the study; if their blood pressure is beyond recommended parameters (140/90 mm Hg) the physician responsible for the patient will administer any medication to control it except for RAS blockers.
A baseline CMR will be performed and repeated at 1-year follow-up. Central analysis of all images will be performed by an independent unit (www. icicorelab. es). Main parameters to be recorded are summarised in box 1. The steering committee in the coordinating centre will determine adjudication of the responsibilities and events according to the criteria defined in the study protocol.
Inclusion criteria
The target population will include patients over 60 years of age with severe AS assessed by transthoracic echocardiography who successfully undergo TAVI following approval by the heart team. Patients must be capable of understanding, accepting and signing informed consent. Successful TAVI procedure will follow the Valve Academic Research Consortium-2 definition of 'device success'. 29 
Exclusion criteria
Patients presenting with any of the following conditions will be excluded from the study: mitral disease requiring intervention, ventricular ejection fraction below 40%, prior myocardial infarction or dilated cardiomyopathy, presence of magnetic resonance incompatibilities (ie, devices, morbid obesity or claustrophobia), use of drugs for RAS blockade within the last 3 months or intolerance, Open Access allergy or contraindication for their use, including glomerular filtration rate below 30 mL/min and persistent hypotension (defined as systolic or diastolic blood pressure <100 or <60 mm Hg, respectively.)
objectives The primary aim is to analyse the impact of ramipril associated with conventional treatment following percutaneous aortic valve replacement in terms of reduction of cardiac mortality, heart failure admissions and cerebrovascular events at 3-year follow-up. Secondary objectives include left ventricular remodelling determined by ventricular mass, fibrosis and ejection fraction as assessed by CMR. Also, functional capacity after 1 year will be analysed.
Statistical analysis
Sample size estimation was based on former studies in patients with AS. [22] [23] [24] First, the study by Dahl et al 27 included 114 patients and evaluated left ventricular mass after 1 year under treatment or standard care with a significant greater reduction of mass in the active group. Analysis of these data suggests the need for at least 79 patients in each group. Second, the research by Goel et al 26 retrospectively
included 1752 patients aiming to analyse the impact on mortality; a propensity score subanalysis including 594 patients reported a 5-year mortality rate of 10% in the active group and 22% in the control group. From these data we estimated that two groups with 150 patients each were necessary. In addition, in the Heart Outcome Prevention Evaluation Study, 30 ramipril was stopped in 7% of the patients due to persistent cough. Taking this into consideration and after fixing α and β errors of 0.05 and 0.20, respectively, we estimate a sample size of 336 patients for the RASTAVI Study (including 5% potential missing subjects).
We will use the C4-Study design pack (Glaxo Welcome, V.1.1) as an independent system for blocked randomisation with balance across groups and blocks of four and six patients that will be randomly selected.
Finally, statistical analysis for categorical variables will be expressed both as absolute values and percentages and for continuous variables as average and SD, median and IQR. Pearson's χ 2 test and Fisher's exact test will be performed for comparisons between groups with qualitative variables, and Student's t-test or Mann-Whitney test for continuous variables. All P values will be bilateral and Figure 1 Schematic workflow for the RAS blockade after TAVI (RASTAVI) Study. 6-MWT: 6-min walk test; CMR, cardiac magnetic resonance; FU, follow-up; RAS, renin-angiotensin system; TAVI, transcatheter aortic valve implantation; TTE, transthoracic echocardiography. Note: telephonic 36-month follow-up visit is allowed.
Open Access will be considered statistically significant when <0.05. Statistical package SSPS V.23 will be used.
Analysis
There is a growing use of TAVI in younger patients and it is expected to become the standard care for AS in the coming years. However, outcomes following TAVI are not benign at all. In this regard, consensus exists regarding the need for measures and therapies that improve the long-term results following percutaneous aortic valve replacement.
The development of left ventricular hypertrophy and fibrosis results in poor outcome in patients with AS 9 10 and the persistence of hypertrophy and diastolic dysfunction after surgical valve replacement increases mortality. 23 24 Likewise, we can assume a similar role of adverse remodelling following TAVI. Moreover, the common presence of other concomitant cardiovascular diseases such as diabetes mellitus or hypertension increases the risk for developing heart failure, reducing the quality of life and survival after TAVI, even in patients without previous myocardial infarction and with preserved left ventricular ejection fraction. For this reason, the first-year readmission rate for any reason (44%), and specifically due to heart failure (12%), still remains high. 31 A putative beneficial effect of RAS blockade after aortic valve replacement has been explored in several studies. A retrospective work in 150 patients showed that RAS blockade reduced hospital admission and deaths. 25 Of note, this effect was independent of left ventricular ejection fraction and volumes, suggesting a benefit of RAS blockade in patients with normal ventricular function and dimensions. A propensity analysis in 1752 patients suggested a better outcome when RAS was pharmacologically blocked. 26 Both studies have important limitations, including their retrospective nature, the lenient inclusion criteria and the lack of information regarding type and dose of drugs given to the patients. Although some authors had suggested a drug class effect of RAS inhibitors, it is generally accepted that there is no such effect given the differences in lipophilia, half life, effect Box 1 Main clinical and imaging parameters that will be recorded for each patient 1) Clinical evaluation ► Age, gender, height, weight, body mass index, body surface, cardiovascular risk factors, medications, familial and personal background, date of first diagnosis of aortic stenosis, former ischaemic cardiomyopathy, former cerebrovascular events, peripheral arterial disease, pulmonary disease, main symptoms (including NYHA class), arterial pressure, heart rate, murmurs, heart failure signs, quality of life questionnaire, frailty evaluation. ► ECG: sinus rhythm, atrial fibrillation, pacemaker, atrial or ventricular hypertrophy. ► Blood tests: haemoglobin, haematocrit, lipids, NT-proBNP, T-Tn, electrolytes, C reactive protein, creatinine, glomerular filtration rate.
2) Transthoracic echocardiography (height, weight, arterial pressure and heart rate will be recorded) ► Left atrium: telediastolic diameters; telesystolic diameters. ► Basal interventricular septum and posterior wall width; LV mass. ► LV telediastolic and telesystolic volume, stroke volume, ejection fraction (Teicholz and Simpson). ► Aortic valve: peak velocity, peak and mean gradient and VTI for LVOT and aortic valve; LVOT diameter, estimated aortic valve area, presence and severity of aortic regurgitation (I/II/III), location of regurgitation (periprosthetic or intraprosthetic). ► Mitral valve: normal; degenerative; rheumatic; severity of regurgitation (I/II/III); mechanism of regurgitation (functional due to annular dilation/ functional due to tenting/rheumatic/ degenerative); ERO. ► Tricuspid valve: TAPSE; lateral S wave; regurgitation; severity of regurgitation (I/II/III); systolic peak gradient between right ventricle and right atrium; dimensions of inferior vena cava and respiratory variations (no/less than 50% or more than 50%). ► Diastolic function parameters: E and A waves; E/A; deceleration time of E wave; isovolumetric relaxation time; E' wave; A' wave.
3) Cardiac magnetic resonance (all exams will be performed with 1.5 Tesla systems, synchronised and during respiratory apnoea; height, weight, arterial pressure and heart rate will be recorded) ► Locators of three planes in the space (axial, coronal and sagittal) enclosing the entire cardiac area. ; right ventricular stroke volume (ml); right ventricular ejection fraction (%); myocardial deformation parameters: strain, strain rate, shift, speed, torsion and torsion rate; longitudinal strain, radial strain and circumferencial strain; quantification of residual aortic regurgitation (regurgitant volume ml; regurgitant fraction, %); presence and degree of myocardial fibrosis: location (subendocardial, subepicardial, intramyocardial), total fibrotic mass (total grams and % of total left ventricular mass). Open Access duration and other pharmacological properties. Ramipril presents a favourable clinical profile and excellent results in prior clinical trials. Yusuf et al demonstrated that ramipril could prevent adverse ventricular remodelling and reduce adverse events including death, myocardial infarction and stroke in patients with high cardiovascular risk and no ventricular dysfunction or heart failure. 30 There is only one prospective study in the surgical setting, with 114 patients, in which candesartan (32 mg per day) was compared with a control group. 27 One year after valve replacement, a reduction in left ventricular mass was more pronounced in the active group. Also, one single study has analysed retrospectively the effects of RAS blockade in patients harbouring a TAVI device suggesting that this therapy could be associated with greater left ventricular mass index regression and reduced all-cause mortality. 32 However, any randomised trial has confirmed this hypothesis. The RASTAVI Study is the first formal attempt to clarify the role of RAS inhibitors in the prognosis of these patients.
Limitations include a potential risk of high unexpected cross-over that might force to increase the number of participating institutions. Also, the unblinded nature of the study for the treating specialist can represent a potential bias that will be addressed by external monitoring of all clinical records and independent central analysis of all imaging parameters by experts in cardiac imaging, unaware of the assignment of the patients.
In conclusion, patients with AS treated with TAVI are at risk for developing persistent left ventricular adverse remodelling, heart failure and, consequently, early mortality. The results of the RASTAVI Study will contribute to improve the management of patients after TAVI and, if the results are positive for the active group, may potentially increase the quality of life, reduce rehospitalisations and improve the long-term survival in this scenario.
Clinical events will be recorded and will be adjudicated by a scientific committee including a clinical cardiologist, an interventional cardiologist and a neurologist who will be blinded to the therapeutic group to which the patient belongs. External independent monitoring of the study will be performed. Anonymised samples and imaging tests will be stored with restricted access to the investigators of the study. Liability insurance will be provided for compensation to those who may potentially suffer harm from trial participation. Only the principal investigator of each participating institution will have access to the final trial data set.
